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Renal survival and prognostic factors in patients with PR3- tibodies (ANCA), which are either directed to myeloper-
ANCA associated vasculitis with renal involvement. oxidase (MPO) or proteinase 3 (PR3) [1–3]. These dis-
Background. Severe renal disease is a feature of anti-neutro- eases can occur in any organ system but the respiratoryphil cytoplasmic antibodies (ANCA)-associated small-vessel
tract and the kidneys are most frequently involved. Un-vasculitis. We evaluated patient and renal survival and prognostic
factors in patients with PR3-ANCA associated vasculitis with treated, WG results in death within weeks to months.
renal involvement at diagnosis during long-term follow-up. Since the introduction of cyclophosphamide and predni-
Methods. Eighty-five patients were diagnosed between 1982 solone as standard treatment, survival has improved dra-and 1996 and followed until 2001 allowing 5 years of follow-
matically from less than 20% at one year reported inup. All patients were treated with prednisolone and cyclophos-
phamide. Univariate and multivariate analyses with patient 1958 [4] to at least a 60% five-year survival reported in
and renal survival as dependent variables were performed. the past ten years [5–8].
Results. Of the 85 patients in this study, 17 (20%) died within Although life-saving in many patients, treatment withone year after diagnosis. Of the 25 patients (29%) who were
cyclophosphamide and prednisolone is associated withdialysis dependent at diagnosis, two remained dependent and
two again became dialysis dependent after less than one year; severe morbidity and mortality, both at short-term and
nine died early without renal recovery. Risk factors for death during long-term follow-up. Initiating aggressive immu-
occurring within one year in univariate analysis (RR, 95% CI) nosuppressive therapy in order to regain or conservewere age 65 years (6.5, 1.6–13.7) and dialysis dependency at
independent renal function in patients with ANCA-asso-diagnosis (3.6, 1.0–13). Twenty patients died beyond one year
during the long-term follow-up. Male gender (4.7, 1.6–10) and ciated vasculitis with renal involvement is, therefore, de-
developing dialysis dependency during follow-up (4.1, 1.4–12) pendent on the perceived prognosis of the patient. Previ-
were associated with poor outcome. Risk factor for renal failure ous studies have associated serum creatinine [9, 10] andwithin one year was dialysis dependency at diagnosis (29, 3.6–
kidney biopsy findings [9–12] at diagnosis, and the occur-229). Of 64 patients dialysis independent one year after diagno-
sis, 12 patients became dialysis dependent during follow-up. A rence of renal relapses [13] with reduced renal survival
renal relapse was strongly associated with development of renal in patients with pauci-immune necrotizing glomerulone-
failure in long-term follow-up (17, 3.5–81). phritis. Recently, we and others observed differencesConclusions. Early death and failure to recover renal func-
between groups associated with the different antigeniction in PR3-ANCA associated vasculitis is associated with
age 65 years and dialysis dependency at diagnosis. Long-term specificity of ANCA [reviewed in 14]. Previously, we
renal survival is determined by renal relapses during follow-up studied the long-term outcome in patients with MPO-
only. Slow, progressive renal failure without relapses is rarely ANCA associated glomerulonephritis and found thatobserved in this group.
proteinuria at diagnosis and during follow-up was the
most important risk factor for the development of renal
insufficiency [15]. Thus far, to our knowledge none ofSmall vessel vasculitides, such as Wegener’s granulo-
the studies have focused on long-term outcome of pa-matosis (WG) and microscopic polyangiitis (MPA), are
tients with PR3-ANCA associated vasculitis with renalstrongly associated with anti-neutrophil cytoplasmic an-
involvement.
In the present study, we retrospectively analyzed pa-Key words: antineutrophil cytoplasmic antibodies, Wegener’s granulo-
matosis, glomerulonephritis, progressive renal disease, proteinase 3. tient and renal survival in patients with PR3-ANCA as-
sociated vasculitis with renal involvement that were diag-Received for publication June 5, 2002
nosed and followed in one single center. We investigatedand in revised form August 14, 2002
Accepted for publication September 24, 2002 predictors of outcome at diagnosis and during follow-
up, and examined the role of non-renal and renal relapses 2003 by the International Society of Nephrology
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on long-term survival and renal outcome in this patient titer [16] were determined, microscopic urinalysis was
performed, and proteinuria and creatinine were deter-population.
mined in a 24-hour urine collection.
METHODS Definitions
Patients Remission was defined as a stabilization or improve-
ment of creatinine clearance in combination with theWe retrospectively identified all consecutive patients
diagnosed with, treated and followed in our hospital for absence of glomerular erythrocyturia and erythrocyte
cell casts and symptoms or signs attributable to activePR3-ANCA positive vasculitis with evidence of renal
involvement (as determined by a biopsy showing necro- extrarenal vasculitis with CRP 10 mg/L. A non-renal
relapse was defined as new or recurrent findings indica-tizing and/or crescentic glomerulonephritis [1] and/or by
deterioration of renal function with glomerular erythro- tive of vasculitic disease without signs of renal involve-
ment [17]. A renal relapse was defined either histopatho-cyturia, erythrocyte casts and proteinuria) between Janu-
ary 1982 and January 1996. Patients were followed until logically by the presence of new necrotizing lesions in a
renal biopsy or clinically by recurrence of microscopicJanuary 2001. Surviving patients thus were followed for
at least five years. glomerular erythrocyturia, erythrocyte cell casts, pro-
teinuria and a decrease in creatinine clearance in a pa-
Treatment and follow-up tient with a previously stable renal function [17]. Micro-
scopic glomerular erythrocyturia was defined as 10 orPatients were treated according to a standardized pro-
tocol [15]. The treatment consisted of oral cyclophospha- more red blood cells, with more than 50% dysmorphic
cells, per high power field (magnification 400) in themide (2 mg/kg) and prednisolone (1 mg/kg body weight)
daily with a maximal oral prednisolone dose of 60 mg/ absence of a urinary tract infection or an indwelling
catheter.day. Doses of cyclophosphamide were adjusted to main-
tain the leukocyte count above 4  109/L. Patients who
Statistical analysespresented with severe vasculitic manifestations such as
alveolar hemorrhage, rapidly rising serum creatinine or Data are presented as mean  standard deviation un-
less stated otherwise. Continuous data between groupsgastrointestinal symptoms were initially treated with in-
travenous methylprednisolone 1000 mg daily for three were compared using the Student t test and the Wilcoxon
signed rank test when appropriate. Survival curves fordays. Plasma exchange was added to the treatment regi-
men in case of disease progression or persistence of ac- patient and renal survival were calculated using Kaplan-
Meier estimates for survival distribution. End point fortive disease. The latter was defined as persistence of
major extrarenal symptoms or the presence of active renal survival analysis was the start of renal replacement
therapy or death due to renal failure. Differences be-necrotizing renal lesions in a repeat renal biopsy after
two to four weeks of immunosuppressive therapy. After tween groups in survival were analyzed with log-rank
test, and multivariate analysis with Cox proportional haz-four to six weeks, the daily prednisolone dose was ta-
pered by 10 mg every two weeks until the dose reached ards analysis with survival time as dependent variable
was performed. Renal survival rates [survival without30 mg, and thereafter by 5 mg every two to four weeks.
Once remission was achieved the daily dose of oral cyclo- end-stage renal disease (ESRD)] are calculated and ana-
lyzed with subjects dying with independent renal func-phosphamide was tapered by 25 mg every three months.
Patients who experienced a renal relapse, or a life-threat- tion censored.
Analyzing patient and renal survival, a large differenceening non-renal relapse, were treated according to the
same protocol. Minor non-renal relapses were treated between both patient and renal survival1 year and1
year after diagnosis became apparent. Survival differ-with 1 mg/kg body weight cyclophosphamide daily and
a maximal oral prednisolone dose of 40 mg/day. ences between groups, therefore, were analyzed sepa-
rately for the time periods 1 year and 1 year afterPatients were hospitalized for at least two to three
weeks or longer when indicated. After discharge, pa- diagnosis (long-term follow-up), to identify risk factors
for these specific time periods. Independent variablestients visited our outpatient clinic at least every two
weeks during the first three months after diagnosis, every tested in the analysis of patient and renal survival 1
year were age, gender, pulmonary involvement (with orfour weeks until one year after diagnosis, and every six
weeks thereafter. At each visit, patients were evaluated without need for mechanical ventilation), CRP level,
serum creatinine level, dialysis dependency, and Bir-by the same physician for signs and symptoms of vasculi-
tic disease and/or adverse effects of the treatment. In mingham Vasculitis Activity Score (BVAS) [18] at diag-
nosis. Variables additionally tested for their associationaddition, blood pressure (BP) and weight were mea-
sured, serum creatinine, erythrocyte sedimentation rate with long-term patient and renal survival (1 year) were
the occurrence of non-renal and renal relapses, cumula-(ESR) and C-reactive protein (CRP) levels, and ANCA
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Table 1. Distribution of disease manifestations at diagnosis usually within days after diagnosis (N 7), and infectious
by organ system
complications of therapy, between three and six months
Organ system N % (N  6; Table 2). Of the seven patients who died of
Renal 85 100 uncontrolled vasculitis, five required dialysis at diagno-
ENT a 72 85 sis; of the six patients who died of infectious causes, two
Musculoskeletal 64 75
were dialysis-dependent at diagnosis. Survival within thePulmonary 47 55
Cutaneous 37 44 first year after diagnosis was age-dependent: compared
Neurologic 34 40 to patients 51 years (N  26) and 51 to 65 years of
Ocular 29 34
age (N  31) at diagnosis, patients 65 years (N  28)Other b 19 22
had a significantly higher risk for death within one year,a ENT, ear nose throat disease
b Including heart and gastrointestinal tract with a relative risk (RR) of 6.5 (95% CI, 1.6–13.7) and
4.0 (1.4–10.5), respectively. Severe renal involvement
was also associated with death within one year (dialysis
dependency at diagnosis: RR 2.9 [1.3–10.8]; serum creati-tive doses of medication, mean arterial pressure (MAP),
nine500 mol at diagnosis: RR 2.2 [0.9–6.9]). In multi-creatinine clearances and proteinuria at 12 months and
variate analysis, CRP level at diagnosis, age, and dialysisuse of angiotensin converting enzyme (ACE) inhibitors.
dependency at diagnosis were associated with mortalityIn multivariate analysis the occurrence of non-renal and
12 months (Table 3).renal relapses were tested as time-dependent variables.
Analyses were performed with SPSS version 10.0 (SPSS
Independence of renal replacement therapy at oneInc., Chicago, IL, USA). A two-sided P value0.05 was
year or lessconsidered to indicate statistical significance.
Of the 25 patients who were dialysis-dependent at
diagnosis, two did not regain renal function (8%) but
RESULTS survived at one year and nine patients (36%) died within
Between April 1982 and January 1996, 85 patients one year (median 1 month, range 4 days to 5 months)
(55 male, 30 female) were diagnosed with PR3-ANCA without regaining independent renal function. Of 14 pa-
positive vasculitis with renal involvement in our hospital. tients (56%) who regained independent renal function,
In all patients, a diagnosis of small-vessel vasculitis was two were only temporarily dialysis-independent and
confirmed by biopsy. Renal involvement was confirmed needed dialysis again within one year; one died within
in 64 by renal biopsy; in the remaining patients renal 12 months. Only 11 of 25 dialysis-dependent patients at
failure, erythrocyturia and erythrocyte casts, and pro- diagnosis (48%) were alive at 12 months with a func-
teinuria was present. Age at diagnosis was 56 17 years. tional renal status. In these 11 patients creatinine clear-
Twenty-five patients (29%) were dialysis dependent at ance at 12 months after diagnosis was 38  14 mL/min.
diagnosis. Forty-seven patients (55%) had pulmonary Only one of 60 patients who were dialysis-independent at
involvement, of whom nine patients (19%) needed me- diagnosis (2%) developed renal failure requiring dialysis
chanical ventilation. Organ manifestations are presented therapy within one year after diagnosis. With univariate
in Table 1.
and multivariate analysis dialysis dependency at diagno-
sis (RR 29, 95% CI 3.6-229) was the only variable associ-Overall
ated with persistent or renewed dialysis dependencyFor the entire group of 85 patients, estimated patient
within one year after diagnosis (Table 4).survival at 5 and 10 years was 73 and 62%, respectively
(Fig. 1). Causes of death are presented in Table 2. Esti- Long-term patient survival
mated median survival was significantly shorter in pa-
Of 68 patients alive at one year, 27 patients (40%) didtients 65 years at diagnosis (3.6 years) when compared
not relapse, 10 patients (15%) experienced only non-to those 51 years (17.8 years) and those 51 to 65 years
renal relapses, and 31 patients (46%) had at least oneof age (17.0 years; P  0.0001; Fig. 2). The estimated
renal relapse, of whom 10 also had one or more non-renalmedian survival for patients who were dialysis dependent
relapses. All relapses were accompanied by the presenceat diagnosis was also significantly shorter than survival
of PR3-ANCA at the time of relapse. The median timein patients who were not on dialysis (9.4 vs. 17.0 years,
to the first non-renal relapse was 3.3 years (range 1.6 torespectively; P  0.013; Fig. 3). Survival with indepen-
10.5). The median time to the first renal relapse was 4.3dent renal function was 65% at 5 years and 51% at 10
years (range 0.8 to 12.2). Twenty patients died more thanyears (Fig. 1).
one year after diagnosis. In univariate analysis, age 65
Mortality within one year years at diagnosis was associated with mortality beyond
one year of follow-up compared to age 51 (RR 10.5,Of the 85 patients, 17 patients (20%) died within one
year. The main causes of death were active vasculitis, 3.6 to 51) and age 51 to 65 (RR 2.9, 1.3 to 11), as was
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Fig. 1. Patient survival () and survival without
need for renal replacement therapy () in 85 patients
diagnosed with proteinase 3–anti-neutrophil cyto-
plasmic antibodies (PR3-ANCA) associated vasculi-
tis with renal involvement. Numbers indicate the
number of patients at risk at 1, 5 and 10 years after
diagnosis.
Table 2. Causes of death ment of the relapse. Five patients developed ESRD after
a median follow-up of 3.0 years after their first renalWithin Follow-up
N (% ) 1 year 1 year relapse. Only two patients progressed to ESRD without
Active vasculitis 7 (19) 7 0 any signs of a renal relapse; these patients had been
Infectiona 12 (32) 6 6 dialysis dependent at diagnosis. In multivariate analysis
Malignancy 3 (8) 0 3
the occurrence of a renal relapse and creatinine clear-Cardiovascular 13 (35) 4 9
Renal insufficiency 2 (5) 0 2 ance, but not proteinuria, at 12 months were highly asso-
Total 37 17 20 ciated with development of dialysis dependency (Table
a 10 during immunosuppressive treatment 4). In contrast, non-renal relapses were not associated
with reduced renal survival (P  0.98). Dialysis depen-
dency at diagnosis also was not associated with the devel-
opment of ESRD in long-term follow-up.male gender (RR 4.7, 1.6 to 10). In multivariate analysis,
development of dialysis dependency was additionally as-
Influence of non-renal and renal relapses onsociated with death, but occurrence of renal or non-renal
renal functionrelapses was not (Table 3).
We further analyzed the influence of renal and non-
Long-term renal survival renal relapses on renal function by comparing creatinine
clearance and proteinuria before, at the moment of, andOf 68 patients alive one year after diagnosis, 64 were
following a first relapse. In addition, the slope of thedialysis independent with a creatinine clearance of 64 
change in creatinine clearance over time was calculated31 mL/min (median 60 mL/min, range 18 to 142 mL/
until three months before the relapse and compared withmin) and proteinuria 0.8 1.0 g/24 h (median 0.3 g/24 h,
the slope starting three months after a relapse. In 31range 0 to 5 g/24 h) at one year. Mean MAP was 101 
patients with a first renal relapse, creatinine clearance10 (median 100, range 83 to 127) at one year and did not
at the moment of relapse had decreased by 15  13.0change throughout the study period (data not shown).
mL/min compared to 12 months before relapse. At 12Forty-four patients (65%) were treated with antihyper-
months following the first renal relapse clearance wastensives, of which 24 were on ACE-inhibitor and/or an-
still 11  11.0 mL/min lower than 12 months before thegiotensin II antagonist. Twelve of 64 patients (19%) who
relapse (Fig. 4A). Proteinuria increased from 0.9  1.2were dialysis independent at one year progressed to
g/24 h 12 months before, to 2.0 1.6 g/24 h at, and 1.1ESRD during the study period; the median time to
1.1 g/24 h 12 months after relapse (Fig. 4B). The slopesESRD in those 12 patients was 4.3 years after diagnosis
of the change in creatinine clearance, excluding the four(range 2.0 to 10.4 years). Five patients who had to start
patients who became dialysis dependent at their firstrenal replacement therapy (RRT) with the occurrence
renal relapse, tended to be more negative following asof a renal relapse (4 patients at the first renal relapse, 1
at the third) did not regain renal function during treat- compared to prior to a renal relapse (	1.8  4.5 mL/
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Fig. 2. Patient survival in 85 patients diag-
nosed with PR3-ANCA associated vasculitis
with renal involvement according to age at
diagnosis. Symbols are: () patients aged
51 at diagnosis; () patients aged 51 to
65; () patients aged65 at diagnosis. Num-
bers indicate number at risk at 1, 5 and 10
years after diagnosis; P 0.0001. Details are
in the text.
Fig. 3. Patient survival in 85 patients diag-
nosed with PR3-ANCA associated vasculitis
with renal involvement according to dialysis
dependency at diagnosis. Symbols are: ()
patients who were not dialysis-dependent at
diagnosis; () patients who were dialysis-
dependent at diagnosis. Numbers indicate
number at risk at 1, 5 and 10 years after
diagnosis; P  0.01. Details are in the text.
min/year before and	3.1  5.2 mL/min/year after renal renal involvement during long-term follow-up. Age 65
years and dialysis dependency at diagnosis were indica-relapse; P  0.06). In contrast, a first non-renal relapse
tive of both poor patient and renal survival. In our long-was not associated with renal function loss or increased
term follow-up analysis, renal function deteriorated dur-proteinuria at the moment of or following the relapse
ing and after a renal relapse, and the occurrence of a(Fig. 4). The slopes of the change in creatinine clearance
renal relapse was the only predictor of an unfavorableafter the first non-renal relapse were not different before
long-term renal prognosis.and after a non-renal relapse (	1.3  2.0 mL/min/year
The patient survival in our study is comparable tobefore and 	0.4  1.5 mL/min/year after non-renal re-
previous studies considering patients with small-vessellapse).
vasculitides with renal involvement where it varied from
59 to 95% in various patient groups during various fol-
DISCUSSION low-up periods [5, 6, 8, 10, 12, 13, 15, 19]. The mortality
The present study evaluated patient and renal survival rate in our series may be somewhat higher as our depart-
ment is a tertiary referral center and patients with severein 85 patients with PR3-ANCA associated vasculitis with
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Table 3. Predictors of patient mortality in multivariate analysis
Predictor RR 95% CI P value
Patient mortality1 year (N 85)
Age at diagnosis 1 year increase 1.10 (1.04–1.16) 0.001
Dialysis dependency diagnosis 3.58 (1.01–12.7) 0.05
CRP level 1 mg/L increase 1.01 (1.00–1.02) 0.045
Patient mortality1 year (N 68)
Age at diagnosis 1 year increase 1.09 (1.03–1.15) 0.002
Male gender 5.75 (1.25–26.5) 0.025
Dialysis dependency follow-up 4.15 (1.43–12.0) 0.009
Table 4. Predictors of renal failure in multivariate analysis
Predictor RR 95% CI P value
Renal failure 1 year (N  85)
Age at diagnosis 1 year increase NS
Dialysis dependency 28.6 (3.58–229) 0.002
Renal failure 1 year (N  64)
Renal relapse 16.8 (3.51–80.8) 0.001
Creatinine clearance at 12 months
1 mL/min decrease 1.14 (1.04–1.22) 0.002
disease at diagnosis are referred to our hospital, while
patients with less severe disease are often managed at
their primary hospital. Mortality shortly after diagnosis
is mostly due to uncontrolled vasculitis, while the other
important cause is severe infectious complications of the
treatment, usually occurring within three to six months
after the initiation of treatment. These findings clearly
highlight the dilemma the clinician treating these pa-
tients must face. Prognostic tools in this respect are there-
fore important to guide the intensity of treatment. Unfor-
tunately, as reported by others [5, 7, 10, 13, 19], early
mortality is strongly associated with older age and more
advanced organ dysfunction caused by the vasculitic pro-
cess. Our results showed that dialysis dependency at
Fig. 4. (A) Creatinine clearances in 44 patients diagnosed with PR3-diagnosis was associated with early mortality, but in con-
ANCA associated vasculitis before, during and after the first non-renaltrast to some other studies [9, 13], lung involvement (with
or renal relapse. (B ) Proteinuria in 44 patients diagnosed with PR3-
or without the need for mechanical ventilation) was not ANCA associated vasculitis before, during and after the first non-renal
or renal relapse. Symbols are: () patients with a renal relapse; ()associated. As can be appreciated from the estimated
patients with a non-renal relapse. Error bars represent SD.survival curve, mortality in the first year after diagnosis
is different compared to follow-up beyond one year.
Therefore, we chose to perform separate analyses for
the time periods within and beyond one year after diag- outcome, as described previously [12, 19, 20]. However,
nosis. For long-term patient survival, no association of of the 25 patients who were dialysis-dependent at diagno-
mortality was found with active vasculitis defined as the sis and regained independent renal function, 11 regained
occurrence of a non-renal or renal relapse; no patients renal function and they had a mean creatinine clearance
died from active vasculitis beyond one year. Long-term of 38 mL/min at one year after diagnosis. We found
mortality was associated with advanced age (as reported that dialysis dependency at diagnosis, and not the serum
previously [7, 8, 10, 20]), male gender and development creatinine level, was associated with the development of
of need for dialysis during follow-up. ESRD, which is in contrast to other studies [8–10, 21].
Fourteen patients (16%) developed ESRD during fol- Renal function at one year after diagnosis was associated
low-up (2 of whom within one year), and two patients with progression to ESRD for patients who experienced
did not recover from dialysis. Dialysis dependency at a renal relapse during follow-up.
In long-term follow-up, it does seem that relativelydiagnosis was highly associated with unfavorable renal
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more patients who were dialysis-dependent at diagnosis ing long-term follow-up, renal relapses are highly associ-
ated with an unfavorable renal outcome, and a renalprogress to ESRD. Five of 11 patients who were dialysis-
dependent at diagnosis but had functional renal status relapse has a significant effect on renal function after
this relapse. Since nearly half of the patients with PR3-at one year progressed to ESRD versus five patients of
53 who were dialysis independent at diagnosis and at ANCA experience relapses, physicians should be alerted
to the potential consequences of a renal relapse. Effortsone year. However, only two patients developed ESRD
gradually, without the occurrence of a renal relapse. The to prevent relapses may be the way to preserve long-
term renal function in this disease.other three patients progressed to ESRD after the occur-
rence of one or more renal relapses. The occurrence of
Reprint requests to Marjan Slot, M.D., Department of Clinical and
a renal relapse was the strongest independent indicator Experimental Immunology, University Hospital Maastricht, P.O. Box
5800 6202 AZ Maastricht, The Netherlands.of a worse renal outcome and carried a high risk for
E-mail: m.slot@immuno.unimaas.nldeveloping ESRD in our patient population. Dialysis
dependency at diagnosis per se was not associated with
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